anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method and apparatus are provided for correlating events in a system.  Problems and other events can, e.g., be detected in a system that generates symptoms or observable events. A computer-accessible codebook is provided that includes a mapping between each of a plurality of groups of possible symptoms and one of a plurality of likely exceptional events (e.g., problems) in the system. The system is monitored and one or more known symptoms generated by the system are detected. A mismatch measure is determined between each of the plurality of groups of possible symptoms in the mapping and the one or more known symptoms using a computer, while disregarding symptoms in the groups of possible symptoms not determined to be known. One or more of the plurality of likely problems is selected corresponding to one of the plurality of groups having the smallest mismatch measure.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to medicine, namely to oncology, and can be used for determining efficiency of treatment of uterine body cancer. Method includes determination of cortisol and tetrahydro-11-deoxycortisol level in day urine 1.5-2 weeks after finishing treatment. Coefficient of ratio of tetrahydro-11-deoxycortisol to cortisol is determined; if ratio value is lower than two, duration of recurrence-free period 5 or more years is predicted, and if ratio is higher than two - development of recurrence in the nearest two years. ^ EFFECT: application of invention makes it possible to select the most efficient preventive therapeutic impact and eliminate additional toxic action of chemical medications. ^ 2 ex
33 children with spastic hemiplegia age between 5-18 years will participate study. Children's gross motor skills classified with Gross Motor Classification Sysytem (GMFCS) and hand abilities classified with Manual Ability Classification System (MACS). The children divided into 3 groups, consecutive mCIMT group, intermittent mCIMT group, and traditional physiotherapy control group. The consecutive mCIMT group received mCIMT treatment for 10 consecutive days in addition to the conventional physiotherapy sessions. A sling used to restrict the noninvolved upper extremity. The unaffected upper extremities of the children restricted for 6 hours and activities performed by using shaping techniques under the guidance of same therapist. Within the remaining period, the family implemented the activities with his/her child that are determined by the therapist using the motor learning principles, appropriate to the age of the child and that he / she likes to do. The assessments performed for all three groups before, 10 days after and 5 weeks after treatment.
Eligible patients with detectable MRD will taper immunosuppressive medications, if applicable, and undergo treatment with blinatumomab. The duration of each cycle of blinatumomab treatment is 6 weeks. Adult and pediatric patients will be treated for 4 weeks followed by a 2-week treatment free period. Patients may receive up to 4 cycles total of blinatumomab therapy.
The invention relates to the technical field of biological products for livestock, and particularly discloses a group I type 4 avian adenovirus strain and application thereof. The group I4 avian adenovirus strain ZMXZAV-4 has a preservation number of CGMCC No. 14296. It has the features of strong cell adaptability, high toxin yield, strong immunogenicity, etc. The triple inactivated vaccine of the newcastle disease virus, the infectious bursal disease virus and the avian adenovirus is invented on the basis of the strain, wherein the newcastle disease virus is a La Sota strain; the infectious bursal disease virus is LY23 strain, and the preservation number is CGMCC No. 11594; the avian adenovirus is group I4 avian adenovirus ZMXZAV-4 strain with preservation number of CGMCC No. 14296. The vaccine is safe and effective, can be used for preventing newcastle disease, infectious bursal disease and avian adenovirus diseases, achieves the effect of preventing three diseases by one injection, and reduces the immunization cost and the immune stress response.
Patients with unresectable HCC with a single nodule ≤ 8 cm or up to three nodules with a diameter of ≤ 5 cm (each). Those patients who fulfil the initial selection criteria will undergo a work-up procedure for further screening of 166Ho-TARE eligibility. If a patient is deemed eligible for 166Ho-TARE, the patient will be included in the study.
A method for evaluating a subject for a biological condition associated with metal metabolism includes sampling positions along a biological sample of the subject to obtain several ion samples. Each ion sample corresponds to a position on the biological sample and each position represents an amount of growth of the biological sample. The obtained ions are analyzed with a mass spectrometer thereby obtaining a plurality of traces. Each such trace represents a concentration of a corresponding elemental isotope, in a plurality of elemental isotopes, over time. A set of features is derived from the traces. Each feature is determined by a variation of a single isotope or a combination of isotopes in the plurality of traces. The set of features is inputted into a trained classifier to obtain a probability that the subject has the biological condition associated with metal metabolism.
OBJECTIVE: Older adults (OA) after mild traumatic brain injury (mTBI) have a high risk of developing persistent post-injury cognitive impairments. Lower pre-morbid cognitive reserve (CR) is increasingly investigated as a risk factor for cognitive dysfunction in OA. However, how CR protects against effects of mTBI at the brain level remains largely understudied.
METHODS: We examined 22 OA who sustained mTBI (mean 67.69 years, SD 5.11) in the sub-acute phase and 15 age- and CR-matched healthy OA (mean 68 years, SD 5.55) performing a three-level visual N-back task using electroencephalography. We calculated inverse efficiency scores of performance from accuracy and reaction times. Event-related potentials served as neurocognitive correlates of attentional (P2) and working memory (P3) processing.
RESULTS: Overall, mTBI OA performed worse than healthy OA (p = 0.031). Lower CR generally decreased performance (p < 0.001). Furthermore, with increasing task difficulty, task performance was more affected by CR (p = 0.004). At the brain level, P2 amplitude was lower in mTBI OA than in healthy OA (p = 0.05). There was no clear effect of CR on P2 or P3 measures.
CONCLUSION: As mTBI OA with lower CR performed worse on a working-memory task, lower CR may be a risk factor for worse recovery after mTBI in this group.
PROBLEM TO BE SOLVED: To obtain a cosmetic, especially a hair cosmetic capable of imparting a rinse effect to hair, by compounding a phosphate ester-modified silicone useful as a component for cosmetics, a specific cationic polymer and, if necessary, a specified component. SOLUTION: This cosmetic contains a phosphate ester-modified silicone of formula I  R is a 1-10C hydrocarbon, etc.; R<1> is R, a group of formula II [M is an alkali metal, etc.; (a), (b) are each 0-50; (x) is 1-15]; (l) is 0-100; (m) is 0-500}, and a cationic polymer in a molar ratio of 0.1/1 to 1/0.01. The compound of formula I includes a compound of formula III, and the cationic polymer includes guar gum.halogenated hydroxyalkyltrialkylammonium ether. When a component selected from anionic surfactants, amphoteric surfactants, and nonionic surfactants is compounded in addition to the above two components, the hair cosmetic capable of imparting the sufficient feelings of satisfaction to users is obtained.
Bangladeshi minor ethnics participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
The assessment of hemostatic disorders in neonates is crucial, but remains challenging for clinicians. Although the concept of developmental hemostasis is widely accepted among hemostasis specialists globally, it is probably under-recognized by clinicians and laboratory practitioners. In parallel with age-dependent hemostatic status maturation, comprehension of the differences between normal values is crucial for the accurate diagnosis of potential hemorrhagic and thrombotic disorders of the vulnerable neonatal population. This review outlines the basics of developmental hemostasis and the features of the available coagulation testing methods, with a focus on novel tools for evaluating the neonatal hemostatic profile. Common errors, issues, and pitfalls during the assessment of neonatal hemostasis are discussed, along with their impact on patient management. Current knowledge gaps and research areas are addressed. Further studying to improve our understanding of developmental hemostasis and its reflection on everyday clinical practice is warranted.
AIM: Parastomal hernia repair is a poorly evidenced area, with uncertainty around the optimum management. There is considerable heterogeneity within the patient cohort, and currently there is no standardization of patient descriptors in the reporting of parastomal hernia repair. The aim of this study was to develop a core descriptor set of key patient characteristics for patients undergoing surgical repair of a parastomal hernia for reporting in all parastomal hernia research.
METHOD: A longlist of descriptors was generated from a review of the existing literature. The longlist was discussed with patients with lived experience of parastomal hernia repair. Colorectal, general and hernia surgeons took part in a three-round international modified Delphi process using a nine-point Likert scale to rank the importance of descriptors. Items meeting predetermined thresholds were included in the final set and discussed and ratified at the consensus meeting.
RESULTS: Seventy seven respondents completed round one, with 23 (29.8%) completing round three. Eighty six descriptors were rated across the three rounds, with 52 descriptors shortlisted. The consensus meeting ratified a final core descriptor set with 19 descriptors across eight domains: anatomy, contamination, disease, previous treatment, risk factors, symptoms, pathway and other hernia.
CONCLUSION: The core descriptor set reflects characteristics that are important to surgeons when reporting on parastomal hernia repair. The use of this agreed core descriptor set may aid the reporting of future studies.
Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
Obese patients with metabolic syndrome(MetS)were correlated with knee joint degeneration and osteoarthritis. However, no studies demonstrate the relationship between patients with metabolic syndrome and degenerate meniscus lesions or knee function. Participants were recruited from First Affiliated Hospital of Jinzhou Medical University. 100 BMI\<24 people without Metabolic syndrome volunteers aged between 35-70 years old and 80 Metabolic syndrome patients with BMI\>27 were included in the study. Obese patients with MetS were assessed knee function and degenerate meniscus tears verified by magnetic resonance imaging. And patients with a mild or no osteoarthritis with Kellgren and Lawrence grade\<2 verified by X ray. We tested the relationship between metabolic syndrome and degenerate meniscus lesions. Obese patients with MetS and volunteers were detected by Mcmurry's test and MRI image to measure degeneration grade of meniscus tears. Number of MetS components were accounted and the knee function KOOS, IKDC score or degenerate meniscus tears were analyzed.
The CSSPT study is a multi-center, randomized, double blinded, placebo-controlled secondary stroke prevention trial in China to determine whether the addition of folic acid and vitamin supplements will reduce recurrent stroke events and other combined incidence of recurrent vascular events and vascular death in patients with recent stroke or transient ischemic attack (TIA). All patients presenting to one of the participating neurologists or general physicians within one months of stroke (ischemic or hemorrhagic) or TIA (eye or brain) are eligible for this trial. Eligible patients will be randomized in a double-blinded fashion to receive multi-vitamins or placebo. The primary outcome event is the composite event "stroke, myocardial infarction, or death from any vascular cause", whichever occurs first. Our target is to recruit a total of 8,000 patients over the two years with a median follow-up of 3 years. Recruitment to the trial began in July 2011 and is planned to continue until December 2013. The investigators aim to complete final follow-up by the end of 2016.
This is a pilot study designed to investigate the dynamic changes in the intestinal microbiome that occur during the course of kidney transplantation, liver transplantation, allogeneic HSCs and mesenchymal stem cells transplantation. Four patient cohorts will be followed. Cohort A: patients receiving kidney transplantation. Cohort B: patients receiving hematopoietic stem cells transplantation. Cohort C: patients receiving mesenchymal stem cells transplantation. Cohort D: patients receiving liver transplantation. Included participants are defined as patients with at least three analyzable stool samples including a baseline sample before the transplantation.
The identification of miRNA-disease associations is crucial for early disease prevention and treatment. However, it is still a computational challenge to accurately predict such associations due to improper information encoding. Previous methods characterize miRNA-disease associations only from single levels, causing the loss of multi-level association information. In this study, we propose TriFusion, a powerful and interpretable deep learning framework for miRNA-disease association prediction. It develops a tri-channel architecture to encode the association features of miRNAs and diseases from different levels and designs a feature fusion encoder to smoothly fuse these features. After training and testing, TriFusion outperforms other leading methods and offers strong interpretability through its learned representations. Furthermore, TriFusion is applied to three high-risk sexually associated cancers (ovarian, breast, and prostate cancers) and exhibits remarkable ability in the identification of miRNAs associated with the three diseases.
Aceituno meal (Simarouba glauca press-cake-obtained by extracting the oil from fruit kernels of Simarouba glauca by pressure) is extracted with water to obtain a new substance of formula C25H36O10 having antiamebic properties. The meal may be soaked in the water to disintegrate the cake, the mixture heated to about 70 DEG  C. with agitation, filtered and washed with hot water.  The filter cake is again extracted with water (containing if desired a small quantity of acetic acid), filtered and washed.  The filtrates and washings are combined and concentrated and any tar or gum which may separate is removed by decantation.  The liquid is further concentrated and a crystalline product allowed to separate.  The crude crystals so obtained are slurried in methanol, refluxed and filtered and the solution concentrated until crystals separate.  The crystals may be further purified by re-dissolving in methanol, filtering the solution through active charcoal and re-crystallizing.  A detailed summary of the complete procedure is given.ALSO:Aceituno meal (Simarouba glauca press-cake-obtained by extracting the oil from fruit kernels of Simarouba glauca by pressure) is extracted with water to obtain a new substance of formula C25H36O10 having antiamebic properties.  The meal may be soaked in the water to disintegrate the cake, the mixture heated to about 70 DEG C. with agitation, filtered and washed with hot water. The filter cake is again extracted with water (containing if desired a small quantity of acetic acid), filtered and washed. The filtrates and washings are combined and concentrated and any tar or gum which may separate is removed by decantation.  The liquid is further concentrated and a crystalline product allowed to separate. The crude crystals so obtained are slurried in methanol, refluxed and filtered and the solution concentrated until crystals separate.  The crystals may be further purified by re-dissolving in methanol, filtering the solution through active charcoal and re-crystallising. A detailed summary of the complete procedure is given.
Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles. Clinical response will be assessed by MRI (volumetrics, primary objective) and audiology at the end of every 3rd cycle. Subjects with volumetric tumor progression will be taken off protocol. Patients who complete 12 cycles of treatment without disease progression, but within the following 24 weeks show subsequent disease progression (defined as \>20% increase in target tumor volume compared to off-treatment volume), will be eligible for re-treatment on study for up to 48 additional weeks, provided they still meet study eligibility criteria.
This multicenter, prospective randomized study is approved by the Institutional Review Boards at both the University Hospitals Case Medical Center, Cleveland, OH, USA and MetroHealth Hospital, Cleveland, OH, USA (Identifiers 07-11-37 and FWA00003938, respectively). Adult women who presented to the Female Pelvic Medicine and Reconstructive Surgery (FPMRS) outpatient clinics at both the University Hospitals Case Medical Center and MetroHealth Hospital with symptoms of stress, urge, or mixed urinary incontinence and who were recommended by the evaluating staff to undergo urodynamic studies (UDS) are eligible. The staff physician will approach the patient for participation in this study after the standard clinic visit is completed and the initial diagnosis is made. A research coordinator will then explain the study and obtain informed consent if the patient agrees to participate. The patient will then be given instructions for a 24 hour pad test and standardized pads to use. The patient will also be given instructions for a three day voiding diary along with routine instruction regarding the urodynamic procedure. The patient will be asked to perform the 24 hour pad test the day prior to the UDS appointment. The three day voiding diary will be performed during a typical and sequential three day period during the week prior to the UDS. Patients will then asked to bring these items to the UDS appointment.

During the initial appointment with the study coordinator, patients will be randomized to 4 groups (A, B, C, and D). Patients in group A will be scheduled to undergo Cough Stress Test (CST) with a comfortably full bladder. This will be subjectively reported by the patient. Patients in group B will be scheduled to undergo CST with an empty bladder after straight catheterization. Group C patients will be scheduled to undergo CST with a bladder infused with 200 cc of saline. Patients in group D will be scheduled to undergo CST with the bladder filled to half functional capacity as determined from the largest voided volume recorded in the patient's voiding diary. CST will be performed in the standing and sitting position for each patient in each of the above groups. The sequence of performing the standing and sitting CST will be randomly assigned for each patient.
Continuous production of polyisobutylene (PIB)-based self-adhesive material with active pharmaceutical ingredients without using solvent or mastication involves charging a continuous compounding machine with a preliminary batch containing granulated PIB etc. and then adding liquid components shortly after starting the compounding process. A process for the continuous production of polyisobutylene (PIB)-based self-adhesive material with at least one active pharmaceutical ingredient (API) in a continuous machine with filling and compounding sections, without solvent and without mastication. The process involves: (a) charging the filling section with a preliminary batch of granulated PIB, release agent(s) and API, optionally with the addition of low-mol. wt. PIB, fillers, plasticisers, tackifiers and/or resins; (b) feeding the charge into the compounding section; (c) possibly adding optional components which were not charged into the filling section; (d) optionally adding other API components; (e) compounding to a homogeneous self-adhesive material; and (f) discharging the product. An Independent claim is also included for a similar process in which the API is/are first added in stage (c) along with any other components not added in (a) and a separate stage (d) as above is omitted.
PCT No. PCT/EP95/02461 Sec. 371 Date Aug. 13, 1996 Sec. 102(e) Date Aug. 13, 1996 PCT Filed Jun. 23, 1995 PCT Pub. No. WO96/00231 PCT Pub. Date Jan. 4, 1996The invention relates to an antisense oligonucleotide suitable for inhibiting the expression of aromatase, the antisense oligonucleotide being obtainable by the following steps: (a) construction of antisense oligonucleotides along the entire length of coding and regulatory regions of an aromatase DNA and/or transcripts thereof, the antisense oligonucleotides overlapping; (b) incubation of an aromatase-expressing cell with one or more of the antisense oligonucleotides of (a); and (c) detection of the inhibition of the aromatase expression as usual, as well as identification of the antisense oligonucleotide(s) responsible for this. Furthermore, the invention relates to a process for preparing such an antisense oligonucleotides as well as its use.
Reading acquisition involves the integration of auditory and visual stimuli. Thus, low-level audiovisual multisensory integration might contribute to disrupted reading in developmental dyslexia. Although dyslexia is more frequently diagnosed in males and emerging evidence indicates that the neural basis of dyslexia might differ between sexes, previous studies examining multisensory integration did not evaluate potential sex differences nor tested its neural correlates. In the current study on 88 adolescents and young adults, we found that only males with dyslexia showed a deficit in multisensory integration of simple nonlinguistic stimuli. At the neural level, both females and males with dyslexia presented smaller differences in response to multisensory compared to those in response to unisensory conditions in the N1 and N2 components (early components of event-related potentials associated with sensory processing) than the control group. Additionally, in a subsample of 80 participants matched for nonverbal IQ, only males with dyslexia exhibited smaller differences in the left hemisphere in response to multisensory compared to those in response to unisensory conditions in the N1 component. Our study indicates that deficits of multisensory integration seem to be more severe in males than females with dyslexia. This provides important insights into sex-modulated cognitive processes that might confer vulnerability to reading difficulties.